EP1011644A4 - Methodes et appareil de traitement de la maladie de parkinson - Google Patents

Methodes et appareil de traitement de la maladie de parkinson

Info

Publication number
EP1011644A4
EP1011644A4 EP97944077A EP97944077A EP1011644A4 EP 1011644 A4 EP1011644 A4 EP 1011644A4 EP 97944077 A EP97944077 A EP 97944077A EP 97944077 A EP97944077 A EP 97944077A EP 1011644 A4 EP1011644 A4 EP 1011644A4
Authority
EP
European Patent Office
Prior art keywords
parkinson
disease
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97944077A
Other languages
German (de)
English (en)
Other versions
EP1011644A1 (fr
Inventor
Moshe Kushnir
Eliahu Heldman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ANALYST RESEARCH LABORATORIES
Neuroderm Ltd
Original Assignee
ANALYST RESEARCH LABORATORIES
ANALYST RES LAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ANALYST RESEARCH LABORATORIES, ANALYST RES LAB filed Critical ANALYST RESEARCH LABORATORIES
Publication of EP1011644A1 publication Critical patent/EP1011644A1/fr
Publication of EP1011644A4 publication Critical patent/EP1011644A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
EP97944077A 1996-10-13 1997-10-09 Methodes et appareil de traitement de la maladie de parkinson Withdrawn EP1011644A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11941796 1996-10-13
IL11941796A IL119417A (en) 1996-10-13 1996-10-13 Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
PCT/IL1997/000327 WO1998016208A1 (fr) 1996-10-13 1997-10-09 Methodes et appareil de traitement de la maladie de parkinson

Publications (2)

Publication Number Publication Date
EP1011644A1 EP1011644A1 (fr) 2000-06-28
EP1011644A4 true EP1011644A4 (fr) 2006-02-08

Family

ID=11069375

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97944077A Withdrawn EP1011644A4 (fr) 1996-10-13 1997-10-09 Methodes et appareil de traitement de la maladie de parkinson

Country Status (6)

Country Link
EP (1) EP1011644A4 (fr)
JP (2) JP2002513389A (fr)
AU (1) AU4570297A (fr)
CA (1) CA2268455C (fr)
IL (1) IL119417A (fr)
WO (1) WO1998016208A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
AU1681799A (en) * 1997-12-17 1999-07-05 Sekisui Chemical Co., Ltd. Percutaneously absorbable levodopa-containing preparation
WO2001001962A1 (fr) * 1999-07-05 2001-01-11 Idea Ag. Procede d'amelioration du transport a travers des barrieres semi-permeables compatibles
US7858112B2 (en) 2002-02-28 2010-12-28 Lintec Corporation Percutaneous absorption system and percutaneous absorption method
JP4608187B2 (ja) * 2002-02-28 2011-01-05 リンテック株式会社 経皮吸収型製剤
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
AT500095B8 (de) * 2004-01-23 2007-02-15 Braun Werner Mag Transdermales abgabesystem
EP2389930A1 (fr) * 2006-03-31 2011-11-30 Erasmus University Medical Center Rotterdam Nouvelle composition pour le controle de la croissance tumorale
JP5902705B2 (ja) * 2010-11-15 2016-04-13 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与
WO2012079072A2 (fr) * 2010-12-10 2012-06-14 Synagile Corporation Compositions de promédicament de lévodopa perfusable par voie sous-cutanée
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
ES2967693T3 (es) 2014-03-13 2024-05-03 Neuroderm Ltd Composiciones del inhibidor de la dopa descarboxilasa
EP3075723B1 (fr) * 2015-03-30 2017-05-24 Berlirem GmbH Esters de glycérol l-dopa hautement solubles
CA3019382A1 (fr) * 2015-03-30 2016-10-06 Berlirem Gmbh Esters de l-dopa solubles dans l'eau
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009051A1 (fr) * 1988-03-29 1989-10-05 Sandoz Ag Deprenyle pour administration transdermique systemique
US4927408A (en) * 1988-10-03 1990-05-22 Alza Corporation Electrotransport transdermal system
WO1995011016A1 (fr) * 1993-10-18 1995-04-27 Teva Pharmaceutical Industries Ltd. R-enantiomere de n-propargyl-1-amino-indane, sels, compositions et utilisation de ce compose

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
JPH04261119A (ja) * 1991-02-13 1992-09-17 Lintec Corp 経皮吸収型貼付剤
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009051A1 (fr) * 1988-03-29 1989-10-05 Sandoz Ag Deprenyle pour administration transdermique systemique
US4927408A (en) * 1988-10-03 1990-05-22 Alza Corporation Electrotransport transdermal system
WO1995011016A1 (fr) * 1993-10-18 1995-04-27 Teva Pharmaceutical Industries Ltd. R-enantiomere de n-propargyl-1-amino-indane, sels, compositions et utilisation de ce compose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9816208A1 *

Also Published As

Publication number Publication date
JP2009001588A (ja) 2009-01-08
IL119417A0 (en) 1997-01-10
IL119417A (en) 2003-02-12
AU4570297A (en) 1998-05-11
WO1998016208A1 (fr) 1998-04-23
JP2002513389A (ja) 2002-05-08
CA2268455C (fr) 2007-05-15
CA2268455A1 (fr) 1998-04-23
EP1011644A1 (fr) 2000-06-28

Similar Documents

Publication Publication Date Title
EP1011644A4 (fr) Methodes et appareil de traitement de la maladie de parkinson
HUP0102951A3 (en) Apparatus for treatment of meniere's disease and similar conditions
AU2830097A (en) Therapeutic method for treatment of alzheimer's disease
EP0907369A4 (fr) Materiaux et procedes de traitement de maladies en plaques
HUP9800033A3 (en) Compositions for the treatment of dermatological disorders and methods for their use
AU2103195A (en) Device and method for treatment of dentition
AU2277595A (en) Device and method for treatment of skin
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
EP0946485A4 (fr) Methode pour le traitement de troubles dermatologiques
AU2209697A (en) Fluorocarbons for diagnosis and treatment of articular disorders
AU1833699A (en) Device and method for treating parkinson's disease
AU4078997A (en) Cholinesterase inhibitors for treatment of parkinson's disease
AU3118699A (en) Apparatus and method for therapeutic treatment of low back pain
IL96915A0 (en) Method and apparatus for fragmentation of hard substances within the human body
AP2001002102A0 (en) Pharmaceutical agents for the treatment of parkinson's disease and adhd and microadenomas
EP0691112A3 (fr) Appareil de traitement opthalmique et son utilisation
ZA9810247B (en) Improved apparatus and method for micro-abrasions of human tissue and/or hides
EP0819008A4 (fr) Methode d'utilisation de lectines dans la prevention et le traitement de maladies et d'affections de la peau
EP0496756A4 (en) Method and apparatus for the treatment and prevention of posture deficiencies of the spine
HK1018271A1 (en) Substituted benzylamines and their use for the treatment of depression
AU4946699A (en) Method of treating meniere's disease and corresponding apparatus
IL119354A0 (en) Method and device for treatment of the brainstem
AU6165898A (en) Method and apparatus for the treatment of strabismus
EP0828507A4 (fr) Technique de traitement de la douleur
EP1009433A4 (fr) Composition therapeutique et procede de traitement

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990512

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE DE FR GB IT NL

A4 Supplementary search report drawn up and despatched

Effective date: 20051223

17Q First examination report despatched

Effective date: 20060707

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEURODERM LTD.

Owner name: ANALYST RESEARCH LABORATORIES

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100504